A randomized trial investigating the superiority of TDM-optimized teicoplanin dosing versus standard of care
Phase 1
Recruiting
- Conditions
- SepsisTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Registration Number
- CTIS2023-503411-15-00
- Lead Sponsor
- Stichting Radboud University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
1.The patient is admitted to the ICU, haematology, MDL or orthopaedics department., 2.The patient is at least 18 years old on the day of inclusion., 3.The patient is treated with teicoplanin as part of standard care., 4.The patient or a representative is willing to sign the Informed Consent Form.
Exclusion Criteria
1. The patient has previously participated in this study., 2.The patient receives any form of RRT other than CVVHD / CVVHDF., 3.Expected duration of teicoplanin therapy is less than 5 days., Pregnant individuals
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method